Journal of Anaesthesiology Clinical Pharmacology

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 32  |  Issue : 1  |  Page : 29--32

Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate


Mohammad Alipour, Masoumeh Tabari, Azadeh Mokhtari Azad 
 Department of Anesthesiology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence Address:
Dr. Mohammad Alipour
Department of Anesthesiology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad
Iran

Background and Aims: Myoclonus is a major side-effect following etomidate injection requiring use of medical intervention. Material and Methods: In this double-blinded clinical trial, 50 consecutive patients, randomly received sufentanil 0.2 μg/kg or midazolam 0.015 mg/kg, 90 s before induction of anesthesia with etomidate (0.3 mg/kg). Then, the patients were monitored for any myoclonic movements during anesthesia. Results: The incidence of myoclonus was 28% in the sufentanil group and 84% in the midazolam group. The frequency and intensity of myoclonus were significantly higher in the midazolam group, compared to the sufentanil group (P < 0.001). Myoclonus duration in the sufentanil and midazolam groups were 5.8 ± 13.2 and 69 ± 47.8 s, respectively (P < 0.0010). Conclusion: The frequency, intensity and duration of myoclonus in the midazolam group, were significantly more prevalent than the sufentanil group.


How to cite this article:
Alipour M, Tabari M, Azad AM. Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate.J Anaesthesiol Clin Pharmacol 2016;32:29-32


How to cite this URL:
Alipour M, Tabari M, Azad AM. Comparative study evaluating efficacy of sufentanil versus midazolam in preventing myoclonic movements following etomidate. J Anaesthesiol Clin Pharmacol [serial online] 2016 [cited 2020 Apr 5 ];32:29-32
Available from: http://www.joacp.org/article.asp?issn=0970-9185;year=2016;volume=32;issue=1;spage=29;epage=32;aulast=Alipour;type=0